| mapping_id,source_concept_id,target_concept_id,predicate,certainty,rationale,extraction_id |
| xw_1988ia_2009ia,figo_endo_1988.stage.IA,figo_endo_2009.stage.IA,narrowMatch,certain,"1988 IA (endometrium only) is subsumed by 2009 IA (no or less than half myometrial invasion).",ex_abu_rustum_1988_stage_i |
| xw_1988ib_2009ia,figo_endo_1988.stage.IB,figo_endo_2009.stage.IA,narrowMatch,certain,"1988 IB (less than half myometrial invasion) maps into 2009 IA.",ex_abu_rustum_1988_stage_i |
| xw_1988ic_2009ib,figo_endo_1988.stage.IC,figo_endo_2009.stage.IB,exactMatch,certain,"1988 IC (half or more) equals 2009 IB (half or more).",ex_abu_rustum_1988_stage_i |
| xw_1988ib_2009ib_conflict,figo_endo_1988.stage.IB,figo_endo_2009.stage.IB,conflict,certain,"The shared code IB denotes opposite extents: 1988 IB is less than half, 2009 IB is half or more (dec_015, section 4). Mapping by code would invert the extent.",ex_abu_rustum_1988_stage_i |
| xw_cnhigh_p53abn,tcga_ucec.molecular_classification.copy_number_high,promise.molecular_classification.p53abn,broadMatch,uncertain,"Copy-number-high is TP53-mutated in about 95 percent of cases (CAP Note E): a surrogate, not an identity (dec_019).",ex_cap_tcga_cn_high |
| xw_2009ia_2023ia1,figo_endo_2009.stage.IA,figo_endo_2023.stage.IA1,narrowMatch,certain,"A non-aggressive 2009 IA with no myometrial invasion and no or focal LVSI is 2023 IA1.",ex_figo2023_stage_ia1 |
| xw_2009ia_2023ia2,figo_endo_2009.stage.IA,figo_endo_2023.stage.IA2,narrowMatch,certain,"A non-aggressive 2009 IA with less than half invasion and no or focal LVSI is 2023 IA2.",ex_figo2023_stage_ia2 |
| xw_2009ia_2023iib,figo_endo_2009.stage.IA,figo_endo_2023.stage.IIB,relatedMatch,certain,"A non-aggressive 2009 IA is raised to 2023 IIB when LVSI is substantial.",ex_figo2023_stage_iib |
| xw_2009ia_2023ic,figo_endo_2009.stage.IA,figo_endo_2023.stage.IC,relatedMatch,certain,"An aggressive 2009 IA with no myometrial invasion is 2023 IC.",ex_figo2023_stage_ic |
| xw_2009ib_2023ib,figo_endo_2009.stage.IB,figo_endo_2023.stage.IB,narrowMatch,certain,"A non-aggressive 2009 IB (half or more) with no or focal LVSI is 2023 IB.",ex_figo2023_stage_ib |
| xw_2009ib_2023iib,figo_endo_2009.stage.IB,figo_endo_2023.stage.IIB,relatedMatch,certain,"A non-aggressive 2009 IB is raised to 2023 IIB when LVSI is substantial.",ex_figo2023_stage_iib |
| xw_2009ib_2023iic,figo_endo_2009.stage.IB,figo_endo_2023.stage.IIC,relatedMatch,certain,"An aggressive 2009 IB (any myometrial invasion) is 2023 IIC.",ex_figo2023_stage_iic |
| xw_iccr_histotype_endometrioid,iccr_endo.histotype.endometrioid,who_fgt.histotype.endometrioid,exactMatch,certain,"ICCR uses the WHO 2020 value list, the same authority this registry's histotype set derives from.",ex_iccr_histotype_endometrioid |
| xw_iccr_histotype_serous,iccr_endo.histotype.serous,who_fgt.histotype.serous,exactMatch,certain,Same WHO 2020 histotype.,ex_iccr_histotype_serous |
| xw_iccr_histotype_clear_cell,iccr_endo.histotype.clear_cell,who_fgt.histotype.clear_cell,exactMatch,certain,Same WHO 2020 histotype.,ex_iccr_histotype_clear_cell |
| xw_iccr_histotype_undifferentiated,iccr_endo.histotype.undifferentiated,who_fgt.histotype.undifferentiated,exactMatch,certain,Same WHO 2020 undifferentiated carcinoma; ICCR does not separately checkbox dedifferentiated.,ex_iccr_histotype_undifferentiated |
| xw_iccr_histotype_mixed,iccr_endo.histotype.mixed,who_fgt.histotype.mixed,exactMatch,certain,Same WHO 2020 mixed carcinoma.,ex_iccr_histotype_mixed |
| xw_iccr_histotype_carcinosarcoma,iccr_endo.histotype.carcinosarcoma,who_fgt.histotype.carcinosarcoma,exactMatch,certain,Same WHO 2020 carcinosarcoma; ICCR carries finer epithelial/sarcomatous and homologous/heterologous sub-detail.,ex_iccr_histotype_carcinosarcoma |
| xw_iccr_histotype_mesonephric,iccr_endo.histotype.mesonephric,who_fgt.histotype.other_not_listed,narrowMatch,certain,Mesonephric carcinoma is named by WHO 2020/ICCR but not itemized here; it is subsumed by the other_not_listed residual.,ex_iccr_histotype_mesonephric |
| xw_iccr_histotype_squamous,iccr_endo.histotype.squamous,who_fgt.histotype.other_not_listed,narrowMatch,certain,Squamous cell carcinoma is a named ICCR/WHO type subsumed by this registry's other_not_listed residual.,ex_iccr_histotype_squamous |
| xw_iccr_histotype_mucinous_gi,iccr_endo.histotype.mucinous_gi,who_fgt.histotype.other_not_listed,narrowMatch,certain,Gastrointestinal-type mucinous carcinoma is subsumed by the other_not_listed residual.,ex_iccr_histotype_mucinous_gi |
| xw_iccr_histotype_mesonephric_like,iccr_endo.histotype.mesonephric_like,who_fgt.histotype.other_not_listed,narrowMatch,certain,Mesonephric-like carcinoma is subsumed by the other_not_listed residual.,ex_iccr_histotype_mesonephric_like |
| xw_iccr_histotype_neuroendocrine,iccr_endo.histotype.neuroendocrine,who_fgt.histotype.other_not_listed,narrowMatch,certain,Neuroendocrine carcinoma is a named ICCR/WHO type subsumed by the other_not_listed residual.,ex_iccr_histotype_neuroendocrine |
| xw_iccr_grade_1,iccr_endo.histologic_grade.1,cap_uterus.histologic_grade.1,exactMatch,certain,Both are FIGO grade 1 (<=5% non-squamous solid growth); ICCR additionally labels it low grade.,ex_iccr_histologic_grade_1 |
| xw_iccr_grade_2,iccr_endo.histologic_grade.2,cap_uterus.histologic_grade.2,exactMatch,certain,Both are FIGO grade 2 (6-50% solid); ICCR additionally labels it low grade.,ex_iccr_histologic_grade_2 |
| xw_iccr_grade_3,iccr_endo.histologic_grade.3,cap_uterus.histologic_grade.3,exactMatch,certain,Both are FIGO grade 3 (>50% solid); ICCR additionally labels it high grade.,ex_iccr_histologic_grade_3 |
| xw_iccr_grade_not_applicable,iccr_endo.histologic_grade.not_applicable,cap_uterus.histologic_grade.high_grade_non_endometrioid,relatedMatch,certain,"ICCR records grade not applicable for tumours high grade by definition (non-endometrioid), where CAP assigns a high-grade non-endometrioid grade value.",ex_iccr_histologic_grade_not_applicable |
| xw_iccr_lvsi_not_identified_cap,iccr_endo.lvsi.not_identified,cap_uterus.lvsi.not_identified,exactMatch,certain,Both denote no tumour within vessels.,ex_iccr_lvsi_not_identified |
| xw_iccr_lvsi_not_identified_figo,iccr_endo.lvsi.not_identified,figo_endo_2023.lvsi.negative,exactMatch,certain,ICCR 'not identified' equals FIGO 2023 'negative' (0 vessels).,ex_iccr_lvsi_not_identified |
| xw_iccr_lvsi_focal_figo,iccr_endo.lvsi.focal,figo_endo_2023.lvsi.focal,relatedMatch,certain,"Both name the sub-substantial present category 'focal', but ICCR's focal ends below 3 vessels and FIGO 2023's below 5, so a 3-4 vessel case is ICCR-substantial yet FIGO-focal.",ex_iccr_lvsi_focal |
| xw_iccr_lvsi_focal_cap,iccr_endo.lvsi.focal,cap_uterus.lvsi.le_4_foci,relatedMatch,certain,"Related present-but-limited categories in different units: ICCR counts vessels (focal is fewer than 3), CAP counts foci (4 or fewer).",ex_iccr_lvsi_focal |
| xw_iccr_lvsi_substantial_figo,iccr_endo.lvsi.substantial,figo_endo_2023.lvsi.substantial,conflict,certain,"Same unit (involved vessels) but different threshold: ICCR/ISGyP substantial is three or more, FIGO 2023 is five or more.",ex_iccr_lvsi_substantial |
| xw_iccr_lvsi_substantial_cap,iccr_endo.lvsi.substantial,cap_uterus.lvsi.ge_5_foci,conflict,certain,ICCR substantial (>=3 vessels) and CAP's 5-or-more-foci choice draw the high-LVSI line at different counts and in different units (vessels vs foci).,ex_iccr_lvsi_substantial |
| xw_iccr_lvsi_indeterminate_cap,iccr_endo.lvsi.indeterminate,cap_uterus.lvsi.cannot_be_determined,relatedMatch,certain,"Related non-committal values but distinct: ICCR 'indeterminate' is genuine doubt whether LVI is present, CAP 'cannot be determined' asserts it could not be assessed (dec_016).",ex_iccr_lvsi_indeterminate |
| xw_iccr_node_itc,iccr_endo.regional_lymph_node_status.itc,ajcc_8.regional_lymph_node_status.pN0_i_plus,exactMatch,certain,"Identical isolated-tumour-cell bound (<=0.2 mm and <=200 cells), recorded pN0(i+).",ex_iccr_regional_lymph_node_status_itc |
| xw_iccr_node_micrometastasis,iccr_endo.regional_lymph_node_status.micrometastasis,ajcc_8.regional_lymph_node_status.pN1mi,exactMatch,certain,Identical micrometastasis bound (>0.2 mm and <=2 mm).,ex_iccr_regional_lymph_node_status_deposit_bounds |
| xw_iccr_node_macrometastasis,iccr_endo.regional_lymph_node_status.macrometastasis,ajcc_8.regional_lymph_node_status.pN1a,broadMatch,certain,"ICCR macrometastasis (>2 mm) is group-agnostic; pN1a is pelvic-specific (para-aortic macro is pN2a), so the ICCR value is broader.",ex_iccr_regional_lymph_node_status_deposit_bounds |
| xw_iccr_mol_polemut_promise,iccr_endo.molecular_classification.polemut,promise.molecular_classification.polemut,exactMatch,certain,ICCR's POLEmut surrogate class is the ProMisE POLEmut class.,ex_iccr_molecular_classification_polemut |
| xw_iccr_mol_polemut_tcga,iccr_endo.molecular_classification.polemut,tcga_ucec.molecular_classification.pole_ultramutated,exactMatch,certain,Pathogenic POLE mutation corresponds to the TCGA POLE-ultramutated group.,ex_iccr_molecular_classification_polemut |
| xw_iccr_mol_mmrd_promise,iccr_endo.molecular_classification.mmrd,promise.molecular_classification.mmrd,exactMatch,certain,ICCR's MMRd surrogate class is the ProMisE mismatch-repair-deficient class.,ex_iccr_molecular_classification_mmrd |
| xw_iccr_mol_mmrd_tcga,iccr_endo.molecular_classification.mmrd,tcga_ucec.molecular_classification.msi_hypermutated,exactMatch,certain,MSH6/PMS2 abnormal expression defines the TCGA MSI-hypermutated group.,ex_iccr_molecular_classification_mmrd |
| xw_iccr_mol_p53abn_promise,iccr_endo.molecular_classification.p53abn,promise.molecular_classification.p53abn,exactMatch,certain,ICCR's p53abn surrogate class is the ProMisE p53-abnormal class.,ex_iccr_molecular_classification_p53abn |
| xw_iccr_mol_p53abn_tcga,iccr_endo.molecular_classification.p53abn,tcga_ucec.molecular_classification.copy_number_high,broadMatch,uncertain,Abnormal p53 IHC is a ~95% surrogate for the sequencing-defined TCGA copy-number-high group (dec_019).,ex_iccr_molecular_classification_p53abn |
| xw_iccr_mol_nsmp_promise,iccr_endo.molecular_classification.nsmp,promise.molecular_classification.nsmp,exactMatch,certain,ICCR's NSMP surrogate class is the ProMisE no-specific-molecular-profile class.,ex_iccr_molecular_classification_nsmp |
| xw_iccr_mol_nsmp_tcga,iccr_endo.molecular_classification.nsmp,tcga_ucec.molecular_classification.copy_number_low,exactMatch,certain,ICCR equates NSMP with the TCGA low-copy-number group.,ex_iccr_molecular_classification_nsmp |
| xw_iccr_stage_ia1,iccr_endo.stage.IA1,figo_endo_2023.stage.IA1,exactMatch,certain,ICCR incorporates the FIGO 2023 staging system verbatim (Note 28).,ex_iccr_stage_IA1 |
| xw_iccr_stage_ia2,iccr_endo.stage.IA2,figo_endo_2023.stage.IA2,exactMatch,certain,ICCR incorporates FIGO 2023 (Note 28).,ex_iccr_stage_IA2 |
| xw_iccr_stage_ia3,iccr_endo.stage.IA3,figo_endo_2023.stage.IA3,exactMatch,certain,ICCR incorporates FIGO 2023 (Note 28).,ex_iccr_stage_IA3 |
| xw_iccr_stage_ib,iccr_endo.stage.IB,figo_endo_2023.stage.IB,exactMatch,certain,ICCR incorporates FIGO 2023 (Note 28).,ex_iccr_stage_IB |
| xw_iccr_stage_ic,iccr_endo.stage.IC,figo_endo_2023.stage.IC,exactMatch,certain,ICCR incorporates FIGO 2023 (Note 28).,ex_iccr_stage_IC |
| xw_iccr_stage_iia,iccr_endo.stage.IIA,figo_endo_2023.stage.IIA,exactMatch,certain,ICCR incorporates FIGO 2023 (Note 28).,ex_iccr_stage_IIA |
| xw_iccr_stage_iib,iccr_endo.stage.IIB,figo_endo_2023.stage.IIB,exactMatch,certain,ICCR incorporates FIGO 2023 (Note 28).,ex_iccr_stage_IIB |
| xw_iccr_stage_iic,iccr_endo.stage.IIC,figo_endo_2023.stage.IIC,exactMatch,certain,ICCR incorporates FIGO 2023 (Note 28).,ex_iccr_stage_IIC |
|
|
